NCT07169500View on ClinicalTrials.gov

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of Young NDMM

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

March 2, 2028

Study Completion Date

March 2, 2030

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

CAR-T

Chimeric antigen receptor T cells (car-t) are genetically engineered MHC independent tumor specific killer cells.

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER